Open AccessOncosurgical Management of Liver Limited Stage IV Colorectal Cancer: Preliminary Data and Protocol for a Randomized Controlled Trial
Author(s) -
Paul Sutton,
Dale Vimalachandran,
Graeme Poston,
Stephen Fenwick,
Hassan Malik
Publication year - 2018
Publication title -
jmir research protocols
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.378
H-Index - 9
ISSN - 1929-0748
DOI - 10.2196/resprot.9453
Subject(s) - medicine , randomized controlled trial , colorectal cancer , protocol (science) , clinical trial , stage (stratigraphy) , cancer , intensive care medicine , surgery , alternative medicine , pathology , paleontology , biology
Background Colorectal cancer is the fourth commonest cancer and second commonest cause of cancer-related death in the United Kingdom. Almost 15% of patients have metastases on presentation. An increasing number of surgical strategies and better neoadjuvant treatment options are responsible for more patients undergoing resection of liver metastases, with prolonged survival in a select group of patients who present with synchronous disease. It is clear that the optimal strategy for the management of these patients remains unclear, and there is certainly a complete absence of Level 1 evidence in the literature. Objective The objective of this study is to undertake preliminary work and devise an outline trial protocol to inform the future development of clinical studies to investigate the management of patients with liver limited stage IV colorectal cancer. Methods We have undertaken some preliminary work and begun the process of designing a randomized controlled trial and present a draft trial protocol here. Results This study is at the protocol development stage only, and as such no results are available. There is no funding in place for this study, and no anticipated start date. Conclusions We have presented preliminary work and an outline trial protocol which we anticipate will inform the future development of clinical studies to investigate the management of patients with liver limited stage IV colorectal cancer. We do not believe that the trial we have designed will answer the most significant clinical questions, nor that it is feasible to be delivered within the United Kingdom’s National Health Service at this current time.